Alise Reicin, M.D.

Alise Reicin, M.D. joined Immatics’ Board of Directors in 2024. In 2020, Dr. Reicin joined Tectonic Therapeutic as President and CEO. Before that, she held leadership positions at several international pharmaceutical companies, including Celgene as President, Global Clinical Development, and EMD Serono as Senior Vice President, Global Head of Clinical Development. Dr. Reicin also held the position of Vice President, Project and Pipeline Leadership, Oncology Franchise, Merck Research Laboratories at Merck & Co. During her tenure, she led the initial development and filing activities that resulted in the first approvals of Keytruda® in the United States and European Union. Dr. Reicin is also a member of the Board of Directors of Sana Biotherapeutics. Alise Reicin was a full-time faculty member at Columbia Medical School as well as a physician and researcher at Columbia Presbyterian Hospital. She received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University.